Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis

BACKGROUND: We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor-mediated phagocytosis, in the SCarlet RoAD (SR) and Marguerite RoAD (MR) phase 3 trials. Several lines of evidence suggested...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Gregory, Delmar, Paul, Voyle, Nicola, Rehal, Sunita, Hofmann, Carsten, Abi-Saab, Danielle, Andjelkovic, Mirjana, Ristic, Smiljana, Wang, Guoqiao, Bateman, Randall, Kerchner, Geoffrey A., Baudler, Monika, Fontoura, Paulo, Doody, Rachelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909550/
https://www.ncbi.nlm.nih.gov/pubmed/31831056
http://dx.doi.org/10.1186/s13195-019-0559-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909550/
https://www.ncbi.nlm.nih.gov/pubmed/31831056
http://dx.doi.org/10.1186/s13195-019-0559-z

Ejemplares similares